Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ECYT
CUSIP29269A10
Phone765-463-7175
Debt
Debt-to-Equity RatioN/A
Current Ratio28.33
Quick Ratio28.33
Price-To-Earnings
Trailing P/E Ratio-17.89
Forward P/E Ratio-25.64
P/E GrowthN/A
Sales & Book Value
Annual Sales$70,000.00
Price / Sales17,952.56
Cash FlowN/A
Price / CashN/A
Book Value$1.99 per share
Price / Book9.02
Profitability
EPS (Most Recent Fiscal Year)($1.00)
Net Income$-55,060,000.00
Net Margins-69,330.66%
Return on Equity-30.87%
Return on Assets-29.67%
Miscellaneous
Employees44
Outstanding Shares70,010,000
Market Cap$1.12 billion
Endocyte (NASDAQ:ECYT) Frequently Asked Questions
What is Endocyte's stock symbol?
Endocyte trades on the NASDAQ under the ticker symbol "ECYT."
How were Endocyte's earnings last quarter?
Endocyte, Inc. (NASDAQ:ECYT) issued its quarterly earnings results on Tuesday, July, 31st. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.00. The biopharmaceutical company had revenue of $0.01 million for the quarter. Endocyte had a negative net margin of 69,330.66% and a negative return on equity of 30.87%. View Endocyte's Earnings History.
When is Endocyte's next earnings date?
What price target have analysts set for ECYT?
4 equities research analysts have issued 12-month target prices for Endocyte's shares. Their predictions range from $21.00 to $21.00. On average, they expect Endocyte's stock price to reach $21.00 in the next year. This suggests a possible upside of 17.0% from the stock's current price. View Analyst Price Targets for Endocyte.
What is the consensus analysts' recommendation for Endocyte?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endocyte in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Endocyte.
Who are some of Endocyte's key competitors?
Some companies that are related to Endocyte include Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX) and Akcea Therapeutics (AKCA).
Who are Endocyte's key executives?
Endocyte's management team includes the folowing people:
- Mr. Michael A. Sherman, CEO, Pres & Director (Age 52)
- Mr. Michael T. Andriole, Chief Financial Officer (Age 45)
- Ms. Katherine K. Parker, VP of HR (Age 53)
- Dr. Alison A. Armour, Chief Medical Officer (Age 54)
- Dr. Christopher P. Leamon Ph.D., VP of R&D (Age 52)
Has Endocyte been receiving favorable news coverage?
Headlines about ECYT stock have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endocyte earned a news and rumor sentiment score of 0.17 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 47.24 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Endocyte.
Who are Endocyte's major shareholders?
Endocyte's stock is owned by many different of institutional and retail investors. Top institutional investors include RA Capital Management LLC (8.07%), BlackRock Inc. (7.44%), Partner Fund Management L.P. (5.81%), FMR LLC (1.27%), Nexthera Capital LP (0.85%) and California Public Employees Retirement System (0.36%). Company insiders that own Endocyte stock include Alison A Armour, Christopher P Leamon and Philip S Low. View Institutional Ownership Trends for Endocyte.
Which institutional investors are selling Endocyte stock?
ECYT stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Bank of America Corp DE, TD Asset Management Inc., California Public Employees Retirement System and Dimensional Fund Advisors LP. Company insiders that have sold Endocyte company stock in the last year include Alison A Armour, Christopher P Leamon and Philip S Low. View Insider Buying and Selling for Endocyte.
Which institutional investors are buying Endocyte stock?
ECYT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., RA Capital Management LLC, Nexthera Capital LP, FMR LLC, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., Alps Advisors Inc. and Swiss National Bank. View Insider Buying and Selling for Endocyte.
How do I buy shares of Endocyte?
Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Endocyte's stock price today?
One share of ECYT stock can currently be purchased for approximately $17.95.
How big of a company is Endocyte?
Endocyte has a market capitalization of $1.12 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe.
How can I contact Endocyte?
Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.
MarketBeat Community Rating for Endocyte (NASDAQ ECYT)
MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe ECYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
